TTI-621: Clinical Trials

2 trials of TTI-621, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 active not recruiting, 1 terminated. 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 22Active not recruiting 1, Terminated 1

Follow TTI-621: new trials by email Literature Review of TTI-621 trials Research Report on TTI-621

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Biospecimen Collection, Computed Tomography, Ontorpacept - Recurrent ALK Positive Large B-Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma
Phase 2Active not recruitingMayo Clinic102023-04-192026-04-22
A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combination With Doxorubicin in People With Leiomyosarcoma
Ontorpacept (TTI-621), Doxorubicin - Leiomyosarcoma
Phase 2TerminatedPfizer762021-06-222024-12-11

Conditions studied

Dermatofibrosarcoma (1)  ·  Hemangiosarcoma (1)  ·  Leiomyosarcoma (1)  ·  Liposarcoma (1)  ·  Lymphoma, B-Cell (1)  ·  Lymphoma, Large B-Cell, Diffuse (1)  ·  Sarcoma (1)

Sponsors

Mayo Clinic (1)  ·  Pfizer (1)

Countries

United States (2)

Top investigators

Stephen M. Ansell, MD, PhD (1)

Results publications

PMID 39319495